Monoclonal antibodies (mAb) are fundamental tools for the advancement of biomedical research and the understanding, detection and treatment of cancer. The Fox Chase Cancer Center (FCCC) Hybridoma Facility has the expertise and resources both for the custom generation of hybridomas and for the production and purification of mAb. The Facility enables a diverse group of scientists, especially those unfamiliar with the specialized methods required to produce hybridomas, to obtain valuable antibody reagents efficiently and economically. As a reflection of this assistance, eight laboratories in the Center have become new users of the Facility since 1999. In addition, the number of laboratories storing cells in the liquid nitrogen freezers maintained by the Facility expanded from 23 to 26, thus reducing the duplication of these freezers in individual laboratories. Currently, investigators outside the Immunobiology Program comprise the major user group in the Center. Overall, 26 investigators with peer-reviewed funding (25% increase since 1999) participating in 8 of the 11 Research Programs, representing all three Divisions of the Center, use the Facility. In 2003, peer-reviewed usage of the Facility was 98%. Since 1999, new Facility services include in vitro production of high-titer mAb (a goal of the last review), quantitation of in vitro murine mAb production by ELISA and monitoring of in vitro production of rabbit, rat and hamster mAb by slide-electrophoresis, purification of mAb, polyacrylamide gel electrophoresis to determine the purity of purified mAb, labeling mAb with fluorescent dyes and production of recombinant IL-6. Demand since the last review has also grown for older services including hybricloma cloning (32% increase) and mAb isotyping (30% increase). Services provided are at near capacity for the Facility staff (1.5 FTE). A future goal of the Facility is to improve the efficiency and cost-effectiveness of producing rabbit hybridomas, as rabbits usually produce high affinity antibodies and are the first choice among many investigators for raising antibodies. The Facility will also generate and select a panel of rat and rabbit monoclonal antibodies that recognize epitope tags that are often engineered into recombinant proteins. Such tag-specific mAb could be used for detection and purification of tagged proteins when a protein-specific mAb is not yet available and would also be useful for sandwich-ELISA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-44
Application #
7310505
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
44
Fiscal Year
2006
Total Cost
$62,821
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336

Showing the most recent 10 out of 1280 publications